ANDA 78626, held by Quagen. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 78626 (Sertraline Hydrochloride), held by Quagen, was first approved by FDA on Jan 31, 2008, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2008 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Jan 18, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 15, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 21, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Feb 21, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 21, 2020 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 5, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 29, 2014 | Supplement 2Manufacturing | Approved | None posted |
| Jun 2, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 26, 2012 | Supplement 3Labeling | Approved | None posted |
| Aug 31, 2009 | Supplement 1Labeling | Approved | None posted |
| Jan 31, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters